AstraZeneca, Cellectis join forces to boost cell, gene therapy innovations
AstraZeneca announced a strategic collaboration and investment agreement with Cellectis, a leader in clinical-stage biotechnology. This partnership, valued initially at $105 million, signifies a substantial move in developing next-generation therapeutics, focusing on areas like oncology, immunology, and rare diseases, where medical needs remain high. Leveraging Gene Editing Technologies for Novel Therapies Under this agreement, AstraZeneca […]